Abstract
Marijuana use in the United States continues to increase with recreational sales legal in 11 states and the District of Columbia and medicinal approval expanded to include over two thirds of states. It is estimated that cannabinoid products are used by 15-40% of individuals with inflammatory bowel disease (IBD). However, the efficacy and safety have not been well-established. It is important that providers are aware of the extent of marijuana use in IBD patients. There is limited information about the frequency that providers inquire about recreational and medicinal use of marijuana. This study evaluated the frequency that providers screen for cannabinoid product use in individuals with IBD.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
